Burning Rock Publishes 2025 Annual Report on Form 20-F
Rhea-AI Summary
Burning Rock Biotech (NASDAQ: BNR) filed its Annual Report on Form 20-F on April 28, 2026, for the year ended December 31, 2025. The filing is available on the SEC website and the company investor site.
The Form 20-F includes the audited consolidated financial statements. Shareholders and ADS holders may request a free hard copy by mail or email to the company.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – BNR
On the day this news was published, BNR declined 12.64%, reflecting a significant negative market reaction. Argus tracked a trough of -14.8% from its starting point during tracking. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $28M from the company's valuation, bringing the market cap to $194.88M at that time.
Data tracked by StockTitan Argus on the day of publication.
Market Reality Check
Peers on Argus
BNR fell 7.88% while peers were mixed: PRE up 6.05%, XGN up 1.86%, BDSX down 6.25%, MDXH down 2.39%, FONR roughly flat at 0.16%, suggesting stock-specific trading rather than a broad sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 02 | Insider share purchase | Positive | -0.6% | Founder disclosed additional ADS purchases totaling 31,487 ADSs in open market. |
| Mar 12 | Earnings results | Positive | -2.6% | Reported 2025 revenue growth, higher gross margin, and lower operating expenses. |
| Jan 05 | Insider share purchase | Positive | +24.4% | Founder announced US$811,721.28 of ADS purchases from the open market. |
| Dec 22 | AGM results | Neutral | -6.9% | All 2025 AGM resolutions passed, including auditor ratification and director re‑elections. |
| Dec 01 | AGM announcement | Neutral | -12.0% | Announced date, agenda and record date for 2025 Annual General Meeting. |
Recent news, including insider buying and earnings, has often been followed by negative price reactions, with only one clear alignment on positive insider purchase news.
Over the past several months, Burning Rock reported improving 2025 fundamentals, including revenue of RMB539.6 million and higher gross margins, while narrowing net losses. Despite this, the stock sold off after the March 2026 earnings release and after the December 2025 AGM outcomes. Founder Yusheng Han disclosed sizable open‑market ADS purchases in January and April 2026, but only the January announcement coincided with a strong positive move. Today’s 20‑F filing formalizes the audited 2025 results already previewed in earlier disclosures.
Market Pulse Summary
The stock dropped -12.6% in the session following this news. A negative reaction despite a routine 20‑F filing fits a pattern where Burning Rock’s shares often declined after various announcements, including earnings and AGM outcomes, regardless of operational improvements. The filing formalizes 2025 results already highlighted in earlier reports, so selling may reflect positioning rather than new financial surprises. Prior episodes show that even insider purchases sometimes coincided with short‑term weakness, underscoring the stock’s sensitivity around disclosure dates.
Key Terms
form 20-f regulatory
u.s. securities and exchange commission regulatory
next generation sequencing medical
precision oncology medical
ads financial
AI-generated analysis. Not financial advice.
GUANGZHOU, China, April 28, 2026 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing technology in the field of precision oncology, announces that on April 28, 2026 it filed its Annual Report on Form 20-F for the year ended December 31, 2025 (the “Form 20-F”) with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F is available for viewing on the SEC website at www.sec.gov and also on the Company’s website at http://ir.brbiotech.com. The Company will provide a hard copy of the Form 20-F containing the audited consolidated financial statements, free of charge, to its shareholders and ADS holders upon request. Requests should be directed to Burning Rock Biotech Limited, No.5 Xingdao Ring Road North, International Bio Island, Guangzhou, or via email at IR@brbiotech.com.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: http://ir.brbiotech.com
Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.
Contact: IR@brbiotech.com
